Published in Br Med J (Clin Res Ed) on January 24, 1987
Calculating confidence intervals for relative risks (odds ratios) and standardised ratios and rates. Br Med J (Clin Res Ed) (1988) 7.41
Association between secretor status and respiratory viral illness. BMJ (1991) 1.47
ABO blood group, secretor status and detection of Helicobacter pylori among patients with gastric or duodenal ulcers. Epidemiol Infect (1991) 1.30
Secretor state of patients with insulin dependent or non-insulin-dependent diabetes mellitus. Br Med J (Clin Res Ed) (1987) 1.19
Increased prevalence of non-secretors in patients with Graves' disease: evidence for an infective aetiology? Br Med J (Clin Res Ed) (1988) 0.94
Lewis phenotype, secretor status, and coeliac disease. Gut (1994) 0.79
Immunoglobulin allotype Gm(1,2;21) in ankylosing spondylitis with peripheral arthritis. Ann Rheum Dis (1988) 0.76
Erythrocyte receptors for (Plasmodium knowlesi) malaria: Duffy blood group determinants. Science (1975) 5.13
Ankylosing spondylitis: klebsiella and HL-A B27. Rheumatol Rehabil (1977) 3.72
Joseph J. Bunim Memorial Lecture. HLA-B27 and the inheritance of susceptibility to rheumatic disease. Arthritis Rheum (1976) 3.16
Faecal carriage of klebsiella by patients with ankylosing spondylitis and rheumatoid arthritis. Ann Rheum Dis (1980) 2.21
Non-secretion of ABO antigens predisposing to infection by Neisseria meningitidis and Streptococcus pneumoniae. Lancet (1986) 2.05
Reiter's syndrome. Evaluation of preliminary criteria for definite disease. Arthritis Rheum (1981) 1.97
Frequency of faecal Klebsiella aerogenes in patients with ankylosing spondylitis and controls with respect to individual features of the disease. Ann Rheum Dis (1980) 1.85
Serum IgG, IgM, and IgA levels in ankylosing spondylitis. Ann Rheum Dis (1973) 1.65
ABO blood groups and cholera. Ann Hum Biol (1977) 1.34
Biochemical evidence that secretor gene, Se, is a structural gene encoding a specific fucosyltransferase. Proc Natl Acad Sci U S A (1984) 1.33
Possible role of blood-group secretory substances in the aetiology of cholera. Trans R Soc Trop Med Hyg (1978) 1.27
Klebsiella related antigens in ankylosing spondylitis. J Rheumatol (1983) 1.19
Acute-phase proteins and serum immunoglobulins in ankylosing spondylitis. Ann Rheum Dis (1983) 1.19
Influence of blood group on the availability of receptors for attachment of uropathogenic Escherichia coli. Infect Immun (1986) 1.14
ABO blood groups, secretor status, salivary protein, and serum and salivary immunoglobulin concentrations. Gut (1971) 1.09
Enteric bacterial agents and the ABO blood groups. Am J Hum Genet (1971) 0.99
A survey of isolates of Klebsiella pneumoniae which cross-react with HLA-B27-associated cell-surface structure on the lymphocytes of patients with ankylosing spondylitis. J Rheumatol (1982) 0.92
Immunoglobulins, secretor status, and the incidence of rheumatic fever and rheumatic heart disease. Hum Hered (1972) 0.92
Arthritis associated with bowel disease. Clin Gastroenterol (1983) 0.90
Postinfective or reactive arthritis. Scand J Rheumatol (1980) 0.85
Blood group, secretor status, and susceptibility to infection by Neisseria gonorrhoeae. Br J Vener Dis (1983) 0.82
Reactive arthritis. Postgrad Med J (1982) 0.82
OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage (2008) 10.99
OARSI recommendations for the management of hip and knee osteoarthritis: part III: Changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage (2010) 7.52
EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis (2006) 6.36
EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis (2006) 4.59
Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum (1998) 4.37
OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthritis Cartilage (2007) 4.34
Sulphasalazine in rheumatoid arthritis. Br Med J (1980) 3.53
Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. Ann Rheum Dis (2007) 2.89
Measurement of joint inflammation. A radioisotopic method. Ann Rheum Dis (1970) 2.35
Total body calcium in rheumatoid arthritis: effects of disease activity and corticosteroid treatment. Br Med J (Clin Res Ed) (1982) 2.24
Antibodies against the mitochondrial fraction of liver after toxic liver damage in rats. Clin Exp Immunol (1966) 2.24
Allergic alveolitis in a maltworker. Thorax (1968) 2.21
Experimentally-induced osteoarthritis in the dog. Ann Rheum Dis (1973) 2.12
Interleukin 1 (IL 1) as a mediator of crystal arthritis. Stimulation of T cell and synovial fibroblast mitogenesis by urate crystal-induced IL 1. J Immunol (1987) 2.12
Tumour necrosis factor in synovial exudates. Ann Rheum Dis (1988) 2.09
Non-secretion of ABO antigens predisposing to infection by Neisseria meningitidis and Streptococcus pneumoniae. Lancet (1986) 2.05
Liver disease in Sjögren's syndrome and rheumatoid arthritis. Lancet (1970) 2.00
An outbreak of meningococcal disease in Stonehouse: planning and execution of a large-scale survey. Epidemiol Infect (1987) 1.95
Ibuprofen in the treatment of rheumatoid arthritis and osteo-arthritis. Ann Rheum Dis (1967) 1.89
Frequency of faecal Klebsiella aerogenes in patients with ankylosing spondylitis and controls with respect to individual features of the disease. Ann Rheum Dis (1980) 1.85
Antibodies in human brucellosis. Br Med J (1967) 1.85
Factors influencing the immune response. I. Effects of the physical state of the antigen and of lymphoreticular cell proliferation on the response to intravenous injection of bovine serum albumin in rabbits. Clin Exp Immunol (1967) 1.85
Bronchodilatation after inhalation of the antihistamine clemastine. Thorax (1978) 1.76
Naturally occurring anti-tissue antibodies in rat sera. Clin Exp Immunol (1966) 1.75
A sequential study of the relationship between faecal Klebsiella aerogenes and the common clinical manifestations of ankylosing spondylitis. Ann Rheum Dis (1982) 1.73
Helicobacter pylori in the mouth--negative isolation from dental plaque and saliva. Eur J Gastroenterol Hepatol (1996) 1.67
Liver disease in rheumatoid arthritis and Sjøgren's syndrome. Prospective study using biochemical and serological markers of hepatic dysfunction. Ann Rheum Dis (1975) 1.66
Derivation of knee joint synovial perfusion. Using the Xenon (133Xe) clearance technique. Ann Rheum Dis (1970) 1.59
Allergic alveolitis in maltworkers. A clinical, mycological, and immunological study. Q J Med (1969) 1.57
Secretor status, smoking and carriage of Neisseria meningitidis. Epidemiol Infect (1990) 1.55
Lymphoedema associated with active inflammatory arthritis in a patient with congenital lymphatic hypoplasia. Br J Rheumatol (1995) 1.55
Frequency and some properties of clinical isolates of methicillin-resistant Staphylococcus aureus. Am J Clin Pathol (1975) 1.54
Increased phagocytic cell activity and anaemia in Corynebacterium parvum treated mice. Br J Exp Pathol (1974) 1.53
Immune response to a soluble protein antigen in NZB mice. Nature (1968) 1.51
Corticosteroids and bone mass in asthma: comparisons with rheumatoid arthritis and polymyalgia rheumatica. Br Med J (Clin Res Ed) (1986) 1.49
Association between secretor status and respiratory viral illness. BMJ (1991) 1.47
High-dose intravenous methylprednisolone in rheumatoid arthritis. Ann Rheum Dis (1982) 1.46
Factors influencing the immune response. 3. The blocking effect of Corynebacterium parvum upon the induction of acquired immunological unresponsiveness to bovine serum albumin in the adult rabbit. Clin Exp Immunol (1968) 1.46
Health economics as an aspect of health outcome: basic principles and application in rheumatoid arthritis. Br J Rheumatol (1995) 1.43
Pyoderma gangrenosum: clinical and laboratory findings in 15 patients with special reference to polyarthritis. Medicine (Baltimore) (1980) 1.41
Immunological responses in Sjogren's syndrome and rheumatoid arthritis. Clin Exp Immunol (1971) 1.41
Effect of Glyvenol (CIBA) on pain and on capillary resistance in rheumatoid arthritis. Ann Rheum Dis (1969) 1.39
Rheumatoid lymphadenopathy. Ann Rheum Dis (1968) 1.39
Antiphospholipid syndrome in pregnancy: a diagnostic dilemma. Med J Aust (1994) 1.39
The distribution of serotypes of Escherichia coli in cow-pats and other animal material compared with serotypes of E. coli isolated from human sources. J Hyg (Lond) (1976) 1.38
Measuring health status in British patients with rheumatoid arthritis: reliability, validity and responsiveness of the short form 36-item health survey (SF-36). Br J Rheumatol (1998) 1.38
Abnormalities in mineral metabolism suggestive of parathyroid over-activity in rheumatoid arthritis. Curr Med Res Opin (1975) 1.36
Is day care equivalent to inpatient care for active rheumatoid arthritis? Randomised controlled clinical and economic evaluation. BMJ (1998) 1.35
Non-steroidal analgesic and anti-inflammatory agents. Br Med J (Clin Res Ed) (1983) 1.35
ABO blood group, secretor state, and susceptibility to recurrent urinary tract infection in women. Br Med J (Clin Res Ed) (1982) 1.35
The serology of autologous immune complex nephritis in the rat. Clin Exp Immunol (1969) 1.33
Adjuvant-induced antired blood cell activity in CBA mice. Clin Exp Immunol (1971) 1.31
ABO blood group, secretor status and detection of Helicobacter pylori among patients with gastric or duodenal ulcers. Epidemiol Infect (1991) 1.30
Depression of lymphocyte responses after surgical trauma. Br J Exp Pathol (1973) 1.29
The Stonehouse study: secretor status and carriage of Neisseria species. Epidemiol Infect (1989) 1.28
A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis. Ann Rheum Dis (2004) 1.28
Non-secretion of ABO blood group antigens predisposing to infection by Haemophilus influenzae. Lancet (1986) 1.26
Expression of purine overproduction in a series of 8-azaguanine-resistant diploid human lymphoblast lines. Proc Natl Acad Sci U S A (1974) 1.25
Mechanisms of macrophage activation. Clin Exp Immunol (1980) 1.25
Stimulation of human purine synthesis de novo by fructose infusion. Metabolism (1975) 1.25
The characteristics of binding of Corynebacterium parvum to glass-adherent mouse peritoneal exudate cells. Clin Exp Immunol (1976) 1.25
Non-specific recognition mechanisms by mononuclear phagocytes. Clin Exp Immunol (1977) 1.25
Dermatitis herpetiformis--a skin manifestation of a generalized disturbance in immunity. Q J Med (1978) 1.24
Signalling cascades in mechanotransduction: cell-matrix interactions and mechanical loading. Scand J Med Sci Sports (2009) 1.20
In vitro binding of Helicobacter pylori to human gastric mucin. Infect Immun (1991) 1.20
Mechanotransduction via integrins and interleukin-4 results in altered aggrecan and matrix metalloproteinase 3 gene expression in normal, but not osteoarthritic, human articular chondrocytes. Arthritis Rheum (2000) 1.19
Secretor state of patients with insulin dependent or non-insulin-dependent diabetes mellitus. Br Med J (Clin Res Ed) (1987) 1.19
Toxigenic bacteria and sudden infant death syndrome (SIDS): nasopharyngeal flora during the first year of life. FEMS Immunol Med Microbiol (1999) 1.18
Activation of the classical and alternate pathways of complement by Corynebacterium parvum. Clin Exp Immunol (1975) 1.18
Factors affecting carriage of Neisseria meningitidis among Greek military recruits. Epidemiol Infect (1992) 1.18
The effect of cigarette smoke on adherence of respiratory pathogens to buccal epithelial cells. FEMS Immunol Med Microbiol (1999) 1.17
The immunologicial consequences of cell death. Lancet (1967) 1.16
Secretory IgA: immune defence pattern in ankylosing spondylitis and klebsiella. Ann Rheum Dis (1981) 1.16
Susceptibility to infection in relation to SIDS. J Clin Pathol (1992) 1.16
Acquisition of Klebsiella aerogenes by neonates. J Med Microbiol (1979) 1.16
Antibiotic sensitivities of Neisseria meningitidis isolates from patients and carriers in Greece. Epidemiol Infect (1992) 1.15
Radioisotope study of small joint inflammation in rheumatoid arthritis. Ann Rheum Dis (1971) 1.15
The in vitro killing of syngeneic cells by peritoneal cells from adjuvant-stimulated mice. Cell Immunol (1975) 1.14
Bone loss in rheumatoid arthritis and primary generalized osteoarthrosis: effects of corticosteroids, suppressive antirheumatic drugs and calcium supplements. Br J Rheumatol (1986) 1.14
Penetration of sodium fusidate (Fucidin) in the synovial cavity. Scand J Rheumatol (1972) 1.13
Integrin and mechanosensitive ion channel-dependent tyrosine phosphorylation of focal adhesion proteins and beta-catenin in human articular chondrocytes after mechanical stimulation. J Bone Miner Res (2000) 1.13
Non-secretion of blood group antigens and susceptibility to infection by Candida species. FEMS Microbiol Immunol (1989) 1.13
Isotope studies in normal and diseased knee joints: 99mTc uptake related to clinical assessment and to synovial perfusion measured by the 133Xe clearance technique. Clin Sci (1971) 1.10
Rheological simulation of synovial fluid by a synthetic polymer solution. Nature (1969) 1.09
Effect of acetazolamide on exercise performance and muscle mass at high altitude. Lancet (1986) 1.09
Integrin-interleukin-4 mechanotransduction pathways in human chondrocytes. Clin Orthop Relat Res (2001) 1.08
Failure to induce tolerance to rat tissue antigens. Immunology (1967) 1.07
Antitissue antibodies and immunological tolerance to self. Arthritis Rheum (1969) 1.07
Chemotaxis of polymorphs induced by tissue antigens and normal serum in rats: a possible clearance mechanism. Clin Exp Immunol (1967) 1.07